Search form



CL Mobile Menu

EULAR: Rheumatoid Arthritis Response Quicker to Certolizumab

EULAR: Rheumatoid Arthritis Response Quicker to Certolizumab

BARCELONA, Spain, June 15 -- Rheumatoid arthritis responds more quickly to investigational certolizumab pegol (Cimzia) than to other tumor necrosis factor-a inhibitors, researchers have found.

Two thirds of RA patients respond within two weeks and almost half have a 50% reduction in symptoms by 24 weeks, according to Ed Keystone, M.D., of the University of Toronto.

"Usually, other (TNF-a) inhibitors plateau at about 24 to 36 weeks, Dr. Keystone said during the European League Against Rheumatism (EULAR) meeting here. "This plateaus at 16 weeks, which means earlier, more robust response or the same robust response achieved earlier."

Dr. Keystone presented preliminary results of a 52-week, placebo-controlled trial of the investigational drug, which combines the TNF-a inhibitor with polyethylene glycol.


By clicking Accept, you agree to become a member of the UBM Medica Community.